Business Context and Reporting Period
This Form 8-K filing by SOBR Safe, Inc. (a Delaware corporation) reports on events occurring between May 13, 2022, and May 18, 2022. The primary event is the entry into a material definitive agreement for an underwritten public offering and the subsequent closing of that offering. The Company's common stock began trading on the Nasdaq Capital Market under the symbol "SOBR" on May 16, 2022.
Key Financial Metrics and Offering Details
- Offering Size: 2,352,942 units sold in a firm commitment underwritten public offering.
- Unit Composition: Each unit consists of one share of Common Stock and two Warrants.
- Offering Price: $4.25 per Unit.
- Warrant Terms: Exercisable immediately at $4.25 per share; expire five years from issuance; non-tradeable.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 352,941 additional shares and/or 705,882 additional Warrants.
- Representative's Warrants: 141,177 warrants issued to the underwriter with an exercise price of $5.3125 (125% of offering price), exercisable from November 17, 2022, to May 17, 2027.
- Outstanding Shares: Following the offering and a 1-for-3 reverse stock split effective April 28, 2022, there are 10,156,081 shares of Common Stock outstanding.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures. It focuses on capital structure changes.
Material Changes
The most significant material change is the capital raise through the public offering, which increased the number of outstanding shares. Additionally, the Company implemented a 1-for-3 reverse stock split effective April 28, 2022, changing the CUSIP to 833592 207. The Company also entered into "lock-up" agreements restricting the sale of securities by the Company, directors, executive officers, and certain stockholders for 180 days (24 months for the Company) commencing May 13, 2022.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. The primary risks and contingencies disclosed relate to the terms of the Underwriting Agreement, including customary indemnification obligations and termination provisions. The Warrants include a provision where the exercise price may adjust downward based on certain events.
Key Facts for Investor Verification
- Verify the total net proceeds received by the Company after deducting underwriting discounts and commissions, as these specific figures are not detailed in the text of this 8-K.
- Confirm the status of the over-allotment option (whether the underwriter exercised the option to purchase additional shares/warrants).
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification liabilities and termination conditions.
- Monitor the Company's cash position post-offering to assess liquidity improvements relative to operational needs.
- Check subsequent filings for any adjustments to the Warrant exercise price based on the "certain events" clause mentioned.